DCPH News and Press, Deciphera Pharmaceuticals Inc. From 06/11/19

Deciphera Pharmaceuticals (NASDAQ: DCPH ) inks agreement with Zai Lab (NASDAQ: ZLAB ) to commercialize ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). More news on: Zai Lab Limited, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

- Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China - - Deciphera To Receive $20 Million Upfront Cash Payment, up to $185 Million in Potential Future Milestones and Royalties - - Deciphera Intends to Expand Ripretinib Development Program in Gastroin...

- DCC-3116 Selectively Targets ULK Kinase, an Initiating Protein that Activates Autophagy - - Company to Host a Webcast on Tuesday, June 18, 2019 at 8 a.m. ET to Discuss Autophagy Inhibition and the Treatment of Mutant RAS Cancers - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Th...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q1 GAAP EPS of -$1.25. More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Top-line Data from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Fourth-line and Fourth-line Plus GIST Patients Expected in Mid-2019 - - Recommended Phase 2 Dose Selected for Part 2 of Phase 1b/2 Study of Rebastinib plus Paclitaxel; Enrollment in Part 2 with Expansion Coho...

Deciphera Pharmaceuticals ( DCPH ) is a small company with a pipeline of small molecules targeting various causes of cancer. Lead candidate Ripretinib is an orally administered kinase switch control inhibitor being developed for the treatment of "gastrointestinal stromal tumors (GIST), advan...